WallStSmart

DaVita HealthCare Partners Inc (DVA)vsGuardian Pharmacy Services, Inc. (GRDN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 842% more annual revenue ($13.64B vs $1.45B). DVA leads profitability with a 5.5% profit margin vs 3.4%. DVA trades at a lower P/E of 16.1x. DVA earns a higher WallStSmart Score of 66/100 (B-).

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22

GRDN

Hold

46

out of 100

Grade: D+

Growth: 6.7Profit: 7.0Value: 5.7Quality: 5.8
Piotroski: 3/9Altman Z: 6.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued
GRDNSignificantly Overvalued (-552.6%)

Margin of Safety

-552.6%

Fair Value

$5.30

Current Price

$37.57

$32.27 premium

UndervaluedFair: $5.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

GRDN3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
6.0610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
26.6%9/10

Every $100 of equity generates 27 in profit

Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
3.4%3/10

3.4% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bull Case : GRDN

The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, EPS Growth, Profit Margin. A P/E of 48.2x leaves little room for execution misses. Thin 3.4% margins leave little buffer for downturns.

Key Dynamics to Monitor

DVA profiles as a value stock while GRDN is a growth play — different risk/reward profiles.

GRDN is growing revenue faster at 17.4% — sustainability is the question.

DVA generates stronger free cash flow (395M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (66/100 vs 46/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions for the long-term care sector, which includes assisted living and skilled nursing facilities. The company is distinguished by its commitment to personalized medication management, ensuring high standards of quality and compliance while delivering exceptional customer service. Leveraging advanced technology and deep pharmaceutical expertise, Guardian aims to enhance patient outcomes and streamline workflows for its healthcare partners. With a strong operational presence across multiple states, the company is well-positioned to address the growing needs for tailored pharmacy services amidst an evolving healthcare landscape.

Want to dig deeper into these stocks?